Innodem Neurosciences utilizes patented mobile eye-tracking technology to develop gaze mapping and eye movement biomarkers that quantitatively assess cognitive function and diagnose neurological disorders. This technology addresses the need for efficient, objective measures in monitoring disease progression in conditions such as multiple sclerosis and Alzheimer's disease.
Funding
$7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
CMVFounders
Product
Problem
Diagnosing and monitoring neurological disorders often rely on subjective assessments and infrequent clinical visits, hindering timely intervention and personalized treatment plans. Traditional cognitive assessments can be time-consuming, require specialized personnel, and may not be sensitive enough to detect subtle changes in cognitive function.
Solution
Innodem Neurosciences offers a mobile eye-tracking platform that uses gaze mapping and eye movement biomarkers to quantitatively assess cognitive function and aid in the diagnosis and monitoring of neurological disorders. The platform employs patented technology to analyze gaze patterns and eye movements during short visual tasks, providing objective measures of cognitive processes such as attention, processing speed, working memory, and response inhibition. By tracking these biomarkers, the technology aims to provide clinicians with sensitive and reliable data to detect subtle changes in cognitive function, monitor disease progression, and personalize treatment strategies. The company's ongoing clinical trials in neurodegenerative disorders provide data to train machine learning algorithms, improving the predictability of the models.
Target Audience
The primary users are neurologists, neuroscientists, and other healthcare professionals involved in the diagnosis, monitoring, and treatment of neurological disorders such as multiple sclerosis and Alzheimer's disease.
Features
- Tablet-based eye-tracking technology for remote and frequent assessments
- Gaze mapping biomarkers (GMBs) that quantify cognitive function through analysis of gaze patterns
- Eye movement biomarkers (EMBs) that aid in the diagnosis and monitoring of neurological disorders
- Machine learning algorithms trained on clinical trial data to improve predictability models
- Commercial clearance in Canada for ETNA™-MS, an eye-tracking neurological assessment for multiple sclerosis